LSM

Cedar Fair Unveils Exciting Capital Plans for 2024 Operating Season

Retrieved on: 
Thursday, August 10, 2023
Theme Parks, Entertainment, Vacation, Specialty, Other Travel, Lodging, Food, Beverage, Destinations, Travel, General Entertainment, Retail, Tourist Attractions, Taste, Splash Works, Dorney Park & Wildwater Kingdom, Camp Snoopy, Kid, Afrolit Sans Frontieres Festival, Cedar Fair, Top, Treats, Sale, Weightlessness, Cedar Point, LSM, Investment, Diving, Water, Trick, Camping, Family, NYSE, Winterfest, Amusement park, Resort, Carowinds

Cedar Fair Entertainment Company (NYSE: FUN), a leader in regional amusement parks, water parks and immersive entertainment, today announced exciting plans for the 2024 operating season across multiple parks in the U.S. and Canada.

Key Points: 
  • Cedar Fair Entertainment Company (NYSE: FUN), a leader in regional amusement parks, water parks and immersive entertainment, today announced exciting plans for the 2024 operating season across multiple parks in the U.S. and Canada.
  • Cedar Point will once again redefine roller coaster innovation in 2024 with the debut of Top Thrill 2, the world’s tallest and fastest triple-launch strata roller coaster.
  • Dorney Park & Wildwater Kingdom is diving into the 2024 season with the debut of Iron Menace, the Northeast's first-ever dive roller coaster, opening in 2024.
  • In addition to new rides and attractions, Cedar Fair will continue to invest in upgrading and expanding food and beverage facilities across its portfolio in 2024.

Avalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth

Retrieved on: 
Monday, July 24, 2023
COVID-19, National Health Laboratory Service, LSM, Acquisition, Laboratory, Genetic testing, MSO, COLA, Pharmaceutical industry, Fine chemical

FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired DE Laboratory LLC (“DE Labs”), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company.

Key Points: 
  • FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired DE Laboratory LLC (“DE Labs”), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company.
  • LSM is now operating this laboratory as a fully owned subsidiary and has invested growth capital for geographical expansion into the surrounding counties.
  • “Our strategy is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services.
  • By leveraging LSM’s experience and infrastructure, we expect to achieve significant synergies with respect to revenue growth and market share.”

Avalon GloboCare’s Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States

Retrieved on: 
Wednesday, July 19, 2023
Aetna, CAP, COVID-19, Genex Power, Genetic testing, Cigna, National Health Laboratory Service, Medicare, LSM, MSA, Laboratory, Master service agreement, Others, LC-MS, Instrumental chemistry, MSO, UnitedHealth Group, Toxicology testing, Pharmaceutical industry, Medicaid

FREEHOLD, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has signed an exclusive Master Service Agreement (“MSA”) with GeneX Laboratory Professional Corp. (“GeneX”). Avalon owns a 40% interest in LSM.

Key Points: 
  • Genex is a CLIA-certified and CAP-accredited laboratory located in Orange County, California that has been dormant and seeking a partner to utilize their valuable license networks.
  • Those tests will now be performed utilizing the LSM infrastructure and resources providing significant expansion opportunity for LSM to perform services through in-network insurance providers previously unavailable.
  • GeneX provides top-tier, comprehensive laboratory testing services and works with major providers in addition to Medicaid in 21 states.
  • By leveraging LSM’s experience and infrastructure, we expect to achieve significant synergies with respect to revenue growth and market shares,” concluded Dr. Jin.

Avalon GloboCare Provides Update on New Commercial Strategy

Retrieved on: 
Monday, July 10, 2023
Insurance, Exhibition, Diabetes, Principal investigator, Genetic testing, Research, MIT, National Health Laboratory Service, LSM, Acquisition, QTY, Laboratory, European, Toxicology, AI, Cytokine, R, Massachusetts Institute of Technology, D, Pharmaceutical industry

FREEHOLD, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today provided the following letter to shareholders from the Company’s President and CEO, David Jin, M.D., Ph.D.:

Key Points: 
  • Avalon is dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services.
  • Our evolving strategy involves acquiring ownership or license rights to precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, share ownership structures or distribution rights.
  • We intend to play a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results.
  • In turn, we believe our profit-sharing arrangement with LSM will result in significant future cash flow to Avalon.

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

Retrieved on: 
Thursday, June 8, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Communication, Nature Medicine, ACAD, Rare disease, Rett syndrome, Quality of life, Vanderbilt University Medical Center, Mutation, MECP2, Daubert v. Merrell Dow Pharmaceuticals, Inc., LSM, Patient, Division, Special education, SE, Safety, Pharmaceutical industry, Pediatrics, Pharmacology

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER™ trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE™ in patients with Rett syndrome five to 20 years of age.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER™ trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE™ in patients with Rett syndrome five to 20 years of age.
  • Change from baseline for all RSBQ domain subscores were numerically in favor of DAYBUE.
  • At week 12 in the DAYBUE and placebo groups, respectively, the mean [SE] Clinical Global Impression–Improvement (CGI-I) scores were 3.5 [0.08] and 3.8 [0.06].
  • “We are pleased that Nature Medicine has published these important results from the pivotal LAVENDER trial,” said Kathie Bishop, Acadia’s Senior Vice President, Chief Scientific Officer and Head of Rare Disease.

Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022

Retrieved on: 
Thursday, April 27, 2023
Avalon, Pharmacogenomics, Pathology, STAT, National Health Laboratory Service, LSM, Laboratory, Toxicology, Genetic testing, Medical device

In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and reference laboratory.

Key Points: 
  • In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and reference laboratory.
  • “We are pleased to report strong financial results and profitability for LSM in 2022, which we believe is further validation of our strategic investment,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
  • “LSM offers an extensive test menu, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, with quick turnaround times.
  • Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more.

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 30, 2023
Health, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Regulation Fair Disclosure, NASH, File, Fatigue, Health care, Disclosure, Medication, COVID, FAQ, Medicines and Healthcare products Regulatory Agency, LSM, Patient, EMM, Treatment, Security (finance), FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Pandemic fatigue, Therapy, Safety, Regulation, Food, MHRA, D, Pharmaceutical industry, Cryptocurrency, Long COVID

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Key Points: 
  • Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  • This randomized, double-blind, placebo-controlled investigation evaluated the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.
  • Financial Performance: Axcella completed registered direct offerings in March 2022 and October 2022, yielding gross proceeds of approximately $59 million.
  • R&D Expenses: Research and development expenses for the quarter and year ended December 31, 2022 were $13.3 million and $57.0 million, respectively.

Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH

Retrieved on: 
Thursday, March 30, 2023
Interim, Non-alcoholic fatty liver disease, Nutrition, Carcinoma, Classification, Liver disease, LACE, Research, MACE, Elastography, Fibrosis, Journal of Clinical Gastroenterology, LSM, HIV disease progression rates, Journal of Clinical Pathology, Patient, Risk, Division, Fatty liver disease, Liver, NAFLD, Mortality, FDA, VCU School of Medicine, Death, Clinical, HCC, Safety, Dietary supplement, Medical imaging, Medicine, Hepatology, Gastroenterology, Physiology

"Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort," was published in the peer-reviewed publication Clinical Gastroenterology and Hepatology .

Key Points: 
  • "Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort," was published in the peer-reviewed publication Clinical Gastroenterology and Hepatology .
  • More than 20% of the US population is affected by NAFLD, which represents a major and growing public health concern with significant health economic implications.
  • While there are no approved curative therapies to date, there are multiple new therapies currently under review with the FDA.
  • Identifying patient populations in the real world who will need these upcoming treatments will be critical when these novel treatments become available.

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, JAK1, American Academy, LSM, Patient, AAD, Week, Safety, American Academy of Dermatology, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
  • Results from the study demonstrate that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index (T-VASI) scores.
  • “Vitiligo is a chronic, immune-mediated disease which, until recently, had limited treatment options available to patients.
  • “As vitiligo can impact patients in different ways, I am encouraged by the continued focus on expanding medical treatment options, and I believe these data highlight the potential of this investigational oral treatment for patients with extensive nonsegmental vitiligo.”

Ace Vision Group Appoints Cristos Ifantides M.D., MBA as Director, Clinical Applications Development

Retrieved on: 
Thursday, February 23, 2023
Aurora, Wills Eye Hospital, School, Sue, University, University of Colorado School of Medicine, Eye, MBA, National Institute for Health and Care Research, Biological engineering, VESA, Drug development, 3D, Research, AVG, Patient, Mount Sinai Hospital, Mount Sinai Hospital (Manhattan), Cataract, Laser, Surgeon, DPT, Health, Micropore particle technology, Presbyopia, College of Engineering (KNUST), Education, LSM, Medical device, Nursing, Hospital, Ophthalmology

BOSTON, Feb. 23, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases caused by ocular rigidity, announced the appointment of Cristos Ifantides, M.D., MBA as Director, Clinical Applications Development effective immediately.

Key Points: 
  • BOSTON, Feb. 23, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases caused by ocular rigidity, announced the appointment of Cristos Ifantides, M.D., MBA as Director, Clinical Applications Development effective immediately.
  • In his new role as Director, Clinical Applications Development, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology platform.
  • Ifantides will spearhead efforts to continue development of the VESA® digital diagnostics artificial intelligence clinical platform.
  • VESA also has broader applications in virtual clinical simulations which could improve technology assisted research validation and test the efficacy of therapeutic interventions in virtual clinical settings.